BioSpace News Archive

IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced the identification of antibody 23-H7, which preclinical data obtained to date indicates provides strong, protective anti-viral effects in SARS-CoV-2 (COVID-19) infected Syrian hamsters via an uncommon mechanism of action.

Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announced results for the quarter ended December 31, 2020 and fiscal year 2020.

SGD Pharma, a leading supplier of glass primary packaging in the pharmaceutical industry and global expert in Type I molded glass, introduces an industry first offering of Type I molded glass vials.

PCR Oncology and Deep Lens today announced a strategic partnership that will integrate artificial intelligence-based clinical trial screening and enrollment platform, VIPER™, into the PCR Oncology network.

Immuneering Corporation today announced Carolina Garcia Rizo, Ph.D., MBA, has joined the company as chief business officer. Dr. Rizo brings to Immuneering extensive experience in the biotech and pharmaceutical industries, including senior-level leadership roles in global business development and strategy, machine learning (ML) based product development and commercial operations.

CARICOM is an organization of 15 states, five associate members and other participants throughout the Caribbean with the primary objectives to promote economic integration and cooperation among its members.

Alvotech strongly disputes AbbVie’s allegations of wrongdoing relating to AVT02, Alvotech’s proposed biosimilar to HUMIRA® (adalimumab).

Gilde Healthcare, a specialized healthcare investor with $1.8 billion under management, announced that its portfolio company, LAVA Therapeutics, has successfully achieved pricing of its Nasdaq initial public offering, expected to result in gross proceeds of approximately $100 million.

Rapid Medical, developer of responsive, adjustable neurovascular devices, announces the FDA clearance of its TIGERTRIEVER™ revascularization device for use in the treatment of ischemic stroke.

Clearsense, an advanced data management and analytics technology platform serving the healthcare industry, announced today it has closed $30 million in financing in partnership led by Health Catalyst Capital.